Research Development Services office will continue to actively support the Mason community during the time of reduced campus operations. All staff will be working remotely but continue to provide support to faculty, students and staff in managing the Limited Submission Opportunities and internal application reviews as needed; creating training materials for proposal development; providing proposal management and support for large, complex, multidisciplinary proposals; and offering guidance on seeking funding opportunities through the Sponsored Programs Innovation Network (SPIN). All staff will be working remotely. Please feel free to contact Rebekah Hersch, Assistant Vice President, Research Development (email@example.com) if you have questions. For information about the Limited Submission Opportunities, please contact Sheila Davis (firstname.lastname@example.org).
COVID-19 Datasets and Analytic Resources
- Academic Data Science Alliance is curating and updating a list of open datasets and analytic resources on their website. You can find more information on available datasets and resources here: www.academicdatascience.org/covid
- NLM released the COVID-19 Open Research Dataset (CORD-19) of scholarly literature related to COVID-19, SARS-CoV-2, and the Coronavirus group. To make full of this dataset, the White House Office of Science and Technology Policy (OSTP) has issued a call for tech and AI experts to develop new text and data mining techniques that can be used to help the science community answer high-priority scientific questions related to COVID-19.
- The Pittsburgh Supercomputing Center (PSC) is currently hosting the COVID-19 database for the National Genomics Data Center of the Chinese People’s Republic. By providing ready access to this important dataset, they hope to enable researchers to better understand the COVID-19 virus. https://www.psc.edu/bridges-for-covid-19-research
- The scientific platform Galaxy at the Pennsylvania State University has developed an open source set of computer tools for helping scientists studying the COVID-19 virus obtain transparent and reproducible results. For more information see https://covid19.galaxyproject.org/
- NVIDIA is providing a software called Parabricks free for 90 days to organizations doing research on COVID19. The Argo cluster meets the minimum requirements. Please contact Jayshree Sarma (email@example.com) if you are interested in using the software. https://blogs.nvidia.com/blog/2020/03/19/coronavirus-research-parabricks/?ncid=em-news-57155#cid=ix01_em-news_en-us . Parabricks software (https://www.developer.nvidia.com/nvidia-parabricks) is used for genome sequencing and uses GPU (Graphical Processing Unit) for speeding up the analysis.
- Georgetown COVID-19 Open Research Dataset: https://pages.semanticscholar.org/coronavirus-research
- The COVID-19 High Performance Computing Consortium: Researchers interested in applying for COVID-19 research allocation on the XSEDE supercomputers can apply here: https://campuschampions.web.illinois.edu
- Facebook Enabling COVID-19 Research with New Data Sets. To support ongoing COVID-19 research and to help inform public health decisions, CMU and UMD made the aggregated data from these surveys publicly available. Learn more here: https://research.fb.com/blog/2020/05/expanding-support-for-covid-19-research-through-the-symptom-surveys/
- The National Science Foundation has awarded the University of Virginia a $1.2 million expansion of a grant to develop a secure, high-performance computing system for research, with the new funds supporting nationwide use of the system for COVID-19 research. Learn more here: https://www.hpcwire.com/off-the-wire/uva-leads-nationwide-project-to-protect-health-data-for-covid-19-research/ (Additional funding is available to all COVID-19 research at Mason)
COVID-19 Funding Opportunities
The following table lists funding opportunities relating to the COVID-19 virus. We will continue to update this list as new opportunities become available. If you would like to add opportunities to this list please feel free to contact Heather Arold at firstname.lastname@example.org.
|Program Title||Sponsor||Deadline||Funding Amount||Brief Synopsis|
|Fast Grants||Emergent Ventures||None Posted||$500,000||Emergent Ventures invites applications from scientists at academic institutions currently working on a COVID-19 related project and in need of funding. Fast Grants will range from $10,000 to $500,000.|
|Notice of Special Interest (NOSI): Urgent Competitive Revisions and Administrative Supplements for Research at NIMHD Research Centers in Minority Institutions (RCMI U54s) on SARS-CoV-2 Vaccine Hesitancy, Uptake, and Implementation||National Institutes of Health/DHSS||5-Mar-21||Not Available||This Notice of Special Interest (NOSI) highlights the urgent need for research strategies and interventions to address SARS-CoV-2 vaccine hesitancy, uptake, and implementation among populations who experience health disparities in the United States (U.S.). Research is urgently needed to understand and address misinformation, distrust, and hesitancy regarding the SARS-CoV-2 (COVID-19) vaccine among adults in the U.S. and its territories, especially among populations who are at increased risk for morbidity and mortality due to long-standing systemic health and social inequities and chronic medical conditions. ThisNOSI solicits community-engaged research to: 1) evaluate innovative interventions to facilitate vaccination uptake in clinical and community contexts; and 2) address the barriers to increasing reach, access, and uptake of vaccinations among health disparity populations. Applications for this NOSI are limited to NIH Research Centers in Minority Institution's (RCMI) currently active U54 awards, which are not in an extension at the time of application submission.|
|Notice of Special Interest (NOSI): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19||National Institute on Drug Abuse/NIH/DHHS||7-May-21||Not Available||NIDA is interested in receiving research applications focusing on individuals with HIV who smoke or vape marijuana, tobacco, cocaine and/or methamphetamine to determine the long-term effects of their use among individuals with HIV and COVID-19.|
|Notice of Special Interest (NOSI): Administrative Supplement Opportunity to Study the Impact of COVID-19 on Global Cancer Prevention and Control||National Cancer Institute/NIH/DHHS||31-Mar-21||$125,000||This Notice of Special Interest (NOSI) informs current awardees that the National Cancer Institute (NCI) is providing the opportunity for supplemental funding to stimulate interest and promote studies on the impact of the COVID-19 pandemic on global cancer prevention and control. This Administrative Supplement is designed to support NCI-funded investigators who have existing relationships/partnerships in low- and middle-income countries (LMICs), inclusive of upper-middle-income countries, to leverage those partnerships to conduct research on the pandemic’s impact on cancer prevention, diagnosis, treatment, and outcomes.|
|Notice of Special Interest (NOSI): Long-Term Neurocognitive Consequences of COVID-19 in Individuals Living with HIV and Substance Use Disorders||National Institute on Drug Abuse/NIH/DHHS||7-May-21||Not Available||NIDA is interested in receiving research applications focusing on studying the long-term neurocognitive consequences of the COVID-19/HIV/SUDs syndemic.|
|Notice of Special Interest (NOSI): Aging-Relevant Behavioral and Social Research on Cornonavirus Disease 2019 (COVID-19)||National Institute on Aging/NIH/DHHS||None Posted||Not Available||NIA is issuing this Notice of Special Interest (NOSI) to highlight the continuing need for behavioral, psychological, social, and economic research on SARS-CoV-2 and coronavirus disease 2019 (COVID-19). There is a need for ongoing research on the longer-term effects of COVID-19 on the health and well-being of those infected, those caring for the sick, and many others whose lives were disrupted by the pandemic and its associated mitigation and prevention strategies. Beyond effects on individuals, this pandemic has brought about unprecedented social and economic disruption that is expected to have long-term and profound effects on the health of the population. These effects will likely be particularly acute for NIH-designated health disparity populations, and other COVID-19 vulnerable groups including older adults, who have experienced higher rates of COVID-19 infection, who in some cases rely on the efforts of paid and unpaid care partners, and who may have additional barriers to accessing the medical system itself. Further, middle-aged and older frontline healthcare and essential workers and their families face unique risks of exposure to both infection and other health-related outcomes by virtue of their employment.|
|Prevention and Control of Infections/Epidemics/Pandemics of Patients at Risk or Infected with HIV and/or TB/HIV in South Africa under the President's Emergency Plan for AIDS Relief (PEPFAR)||Center for Global Health/CDC/DHHS||13-Mar-21||$10,000,000||This NOFO aims to decrease iatrogenic infections of people living with HIV (PLHIV) in South Africa at the facility (such as health and correctional facilities) and community levels. PLHIV are at higher risk of contracting or developing serious complications from infectious diseases such as tuberculosis (TB) and Coronavirus Disease 2019 (COVID-19). Existing Infection Prevention Control (IPC) guidelines often 1) do not address present epidemic/pandemic challenges, 2) provide conflicting recommendations, or 3) fail to address serious IPC concerns such as facility partial or total closure, facility cleaning and disinfection, staff quarantine, and staff isolation. This lack of clarity and frequent but necessary IPC guidelines updates often leads to confusion and anxiety among stakeholders.|
|Global Problem Solver Challenge||Cisco Systems, Inc.||29-Jan-21||$1,000,000||The fifth annual Cisco Global Problem Solver Challenge aims to recognize new business ideas that leverage technology for social impact from early-stage entrepreneurs around the world. Cisco is committed to positively impacting 1 billion people by 2025. As part of our work, the sponsor seeks to inspire and empower a generation of global problem solvers who will not only survive – but drive and thrive – in our increasingly digital economy. With the Internet of Things (IoT) and digital technologies connecting devices and data, good ideas now have the ability to make a difference more quickly than ever before. $1,000,000 USD in prize money will help accelerate the adoption of breakthrough technology, products, and services that drive economic development and/or solve social or environmental problems.|
|Notice of Special Interest (NOSI): Promoting Research on COVID-19 and Rheumatic, Musculoskeletal and Skin Diseases||National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS||5-Feb-21||Not Available||The purpose of this Notice is to announce to potential applicants to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) an interest in research on the impact of COVID-19 as related to diseases and conditions within the NIAMS mission.|
|Grand Challenge - COVID-19 Data Science Grants||International COVID-19 Data Alliance||1/19/2021||$100,000||ICODA and Grand Challenges are delighted to launch the new pilot Grand Challenges ICODA COVID-19 Data Science grant programme that will focus on addressing major questions about how to reduce the harm of COVID-19 and future pandemics. The programme aims to unite data and develop processes, analytical tools and infrastructure to achieve rapid scientific progress and impact. The Grand Challenges ICODA COVID-19 Data Science grant programme will provide awards of up to US$100,000 for studies lasting for between 6-12 months, starting in mid-March 2021 onwards. In addition, successful applicants will have access to ICODA’s digital workbench, as well as technical and wider support from ICODA and its partners.|
|COVID-19 Vaccine: Safety and Immunization Monitoring||Asian Development Bank||1/31/2021||$50,000||As part of its work to address COVID-19 within the region, ADB is launching a three-part COVID-19 Vaccine Challenge Series. The COVID-19 Vaccine Challenge Series aims to find several digital solutions that will help ADB's developing member countries tackle a broad range of challenges as vaccines become available - from vaccine delivery and monitoring of healthcare workers and volunteers, as well as safe and efficient administration of COVID-19 vaccines. This challenge is the first part of the COVID-19 Vaccine challenge series and aims at addressing the two challenges below.|
|Notice of Special Interest (NOSI): Limited Competition for Emergency Competitive Revisions for Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 from Skin and the Oral Cavity for Rapid Acceleration of Diagnostics Radical (RADx-rad)||National Institutes of Health/DHHS||None Posted||$500,000||NIH is issuing this NOSI in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency NOSI from the National Institutes of Health (NIH) provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. The goal of the RADx-rad initiative is to encourage the development of novel, non-traditional approaches to identify the current SARS-CoV-2 virus or other markers of the COVID-19 disease that can be used in future outbreaks of COVID-19 and that could be applicable to other, as yet unknown, viruses. Specifically, the goal of this NOSI is to advance early stage biosensing technologies intended for the detection of volatile organic compounds (VOCs) emanating from skin and/or multiple (i.e., biologic, chemical and physical) biosignatures captured from the oral cavity in COVID-19. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.|
|Notice of Special Interest (NOSI): Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences||National Institutes of Health/DHHS||None Posted||Not Available||This Notice of Special Interest (NOSI) highlights the urgent need for social, behavioral, economic, health communication, and epidemiologic research relevant to the 2019 Novel Coronavirus (SARS-CoV-2) and COVID-19. This NOSI encourages urgent competitive supplements and administrative supplements to existing longitudinal studies that address key social and behavioral questions related to the COVID-19 pandemic, including adherence to and transmission mitigation from various containment and mitigation efforts; social, behavioral, and economic impacts from these containment and mitigation efforts; and downstream health impacts resulting from these social, behavioral, and economic impacts, including differences in risk and resiliency based on gender, race and ethnicity, socioeconomic status, and other social determinants of health.|
|Strengthening Public Health Research and Implementation Science (Operations Research) to Control and Eliminate Infectious Diseases Globally||Center for Global Health/CDC/DHHS||20-Jan-21||$10,000,000||The purpose of this NOFO is to: conduct and monitor epidemiologic and laboratory-based science, surveillance, and research related to COVID-19 and other global public health threats in Africa, Southeast Asia, Eastern Europe and Central Asia, and the Middle East and North Africa (MENA), including, but not limited to, assessments of the extent of pathogen exposures or transmission based on serologic testing, improved understanding of immune responses to infectious pathogens, and assessments of various approaches to collecting and analyzing the results of serologic testing; and incorporate the results of these public health activities into operational disease detection, prevention, and response or control programs in regions noted above, strengthen public health capacity as outlined in the Global Health Security Agenda, and disseminate findings across the region, with partners, and globally.|
|Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19)||National Center for Advancing Translational Sciences/NIH/DHHS||None Posted||Not Available||NCATS is issuing this Notice of Special Interest to highlight the urgent need for research on the 2019 novel coronavirus and the disease it causes, i.e. "coronavirus disease 2019" (COVID-19). NCATS is particularly interested in projects that repurpose existing drugs or biologics (existing therapeutics) that have already begun or completed a Phase I clinical trial.|
|Notice of Special Interest (NOSI): Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel Coronavirus||National Institutes of Health/DHHS||15-Apr-21||Not Available||NIMH is issuing this Notice of Special Interest (NOSI) to highlight interest in research to strengthen the mental health response to Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and to future public health emergencies, including pandemics. NIMH is especially interested in research to provide an evidence base for how a disrupted workforce may adequately respond/adapt to and maintain services or provide additional care for new or increasing mental health needs, as well as to learn about the effects of the virus and public health measures to prevent spread of COVID-19 that may have an impact on mental health. Research addressing the intersection of COVID-19, mental health, and HIV treatment and prevention are also of interest to NIMH.|
|Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)||National Institutes of Health/DHHS||1-May-21||Not Available||NIA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19). The mission of NIA is to support and conduct genetic, biological, clinical, behavioral, social, and economic research on aging. This NOSI supports mission critical areas of research for NIA as they relate to the COVID-19 pandemic.|
|Dear Colleague Letter: Future of International Research Collaboration Post COVID-19||National Science Foundation||31-Mar-21||$300,000||The NSF Office of International Science and Engineering (OISE) seeks to understand the nature and scope of COVID-19 impacts on international collaboration in research and education. OISE further seeks to encourage creative efforts to leverage the unique moment to enable more robust, resilient and sustainable collaborations. OISE anticipates that documenting and sharing lessons will strengthen future international collaboration efforts.|
|Notice of Special Interest (NOSI): Research on Rehabilitation Needs Associated with the COVID-19||National Institutes of Health/DHHS||5-Feb-20||Not Available||The purpose of this Notice of Special Interest is to encourage applications in three areas related to the intersection of COVID-19, the associated mitigation actions, and rehabilitation:|
|COVID-19 Medical Countermeasures Consultant Support||Department of Defense||None Posted||Not Available||1. Scope: The current COVID-19 pandemic demands immediate action in developing life-saving Medical Countermeasures (MCM), which encompass technical efforts from early development through their Food and Drug Administration (FDA) approval. This document provides a summary of the Department of Defense (DOD) and Operation Warp Speed (OWS) major integrated efforts that include but are not limited to leveraging the use of Senior Subject Matter Experts (SMEs) consultants with recognized expertise in MCM development in a variety of disciplines, such as: diagnostics, vaccines, polyclonal antibodies (pAbs), and large and small molecule drug development efforts from early development through FDA approval and Post Licensure related efforts. The Government will draw upon consultant expertise of SMEs to support the Joint Program Executive Office, Chemical, Biological, Radiological & Nuclear Defense (JPEO-CBRND) mission through the development of MCM in the three major MCM domains: Diagnostics, Prevention, and Treatment for COVID-19. SMEs will include senior pharmaceutical technical experts to ensure the JPEO can accomplish the mission to deliver MCMs to DoD personnel and to the nation. Nested within these major integrated MCM development efforts are numerous technical challenges to clinical, non-clinical, and manufacturing processes, up to full scale production to obtain FDA approval. The consultant pharmaceutical SMEs will augment DOD MCM developers and contribute to analysis, assessment, design, and evaluation of alternative approaches to achieve the rapid development of MCMs against COVID-19. They will increase efficiency and effectiveness, reduce the risks, and shorten the schedule of delivering MCMs to protect the U.S. military, coalition forces, and the nation from the current COVID-19 pandemic. 2. The Government has determined that the need to accelerate COVID-19 development is of such an unusual and compelling urgency (FAR.6.302-2) that the Government has pursued a sole source procurement for the consultant services described above. The contract will have a Base Period of six (6) months duration, with the option to extend services in accordance with FAR 52.217-9 for a further six months.|
|Competitive Fund for Peace and Recovery||Innovations for Poverty Action||None Posted||Not Available||The Peace & Recovery (P&R) Program supports field experiments and related research on reducing violence and fragility, promoting peace, and preventing, managing, and recovering from crises. Currently, the sponsor is accepting Research Proposals for COVID-19 Response and Off-Cycle Research Proposals for Research on Homicide Reduction in Latin America and the Caribbean.|
|RFA-HD-21-023 -- NICHD Program Project Grants for HIV Research (P01 Clinical Trial Optional)||National Institute of Child Health and Human Development||1-Mar-21||$3,000,000||This Funding Opportunity Announcement (FOA) invites submission of Program Project (P01) applications to support integrated, multi-project research programs that address HIV scientific areas relevant to the NICHD mission as a well-defined, central research focus or objective.|
|Small Grants Program in Behavioral Economics||Sage (Russell) Foundation||None Posted||$8,500||The Russell Sage Behavioral Economics Roundtable supports a small grants research program to support high quality research in behavioral economics and to encourage young investigators (Ph.D. students and recent graduates) to enter this developing field.|
|COVID-19 Vaccines: Accelerating Vaccine Development and Global Manufacturing Capacity to Stop the Pandemic||Coalition for Epidemic Preparedness Innovations (CEPI)||None Posted||Not Available||The objective of this Call for Proposals is to support the rapid development of vaccines against COVID-19 with a goal of achieving licensure/emergency authorisation in 12-18 months or less and to ensure the availability of sufficient doses for wide-spread global deployment as soon as possible in 2021.|
|SARS-CoV-2 (COVID-19) Program Activities||Assistant Secretary of Health/DHHS OS-PAW||None Posted||None Posted||The Office of the Assistant Secretary for Health (OASH) has established the Laboratory and Diagnostics Working Group (LDWG) seeking submissions to a Broad Agency Announcement (BAA) “to prevent, prepare for, and respond to coronavirus, domestically or internationally, for necessary expenses to research, develop, validate, manufacture, purchase, administer, and expand capacity for COVID–19 tests to effectively monitor and suppress COVID–19…” (Paycheck Protection Program and Healthcare Enhancement Act (P.L. 116-139)). OASH/LDWG seeks proposals for projects that will further enable the coordination and development of testing and associated products that meet the current and future needs, and the effective transition of technology into broad use without impediments. The primary areas of focus should specifically include (1) Scaling and Networking of Technologies, and (2) Testing Demonstrations & Technical Assistance. Specifically, OASH is interested in submissions that will substantially increase our testing capacity and quality in the near term, and do not fall within the scope of other HHS programs.|
|Prototype development of a COVID-19 Pandemic Therapeutic Rapid Advanced Research and Development (ARD) to Large Scale Manufacturing||Department of the Army||28-Feb-21||Not Available||Prototype development of a COVID-19 Pandemic Therapeutic Rapid Advanced Research and Development (ARD) to Large Scale Manufacturing. This Prototype project is a combination of an agile development activity, design, and demonstration of the technical and operational utility of a product to move forward to FDA licensure/approval.|
|6640--COVID-19 Cephieid Equipment COVID-19 Testing Emergency Requirement||Department of Veterans Affairs||None Posted||Not Available||Description of Supplies or Services: The estimated value of the proposed action is $ 323,040.00. Cepheid has developed an automated molecular test for the qualitative detection of SARS-CoV2, the virus that causes COVID-19 on the GeneXpert Systems. Cepheid is the only authorized US manufacturer and distributor of this instrumentation for polymerase chain reaction (PCR) molecular technology. These instruments are also compatible and will integrate with systems currently installed in the facilities, streamlining the validation and implementation process.|
|Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)||National Institutes of Health/DHHS||None Posted||Not Available||National Institutes of Health (NIH) hereby notify Program Directors/Principal Investigators (PD(s)/PI(s)) holding specific types of NIH research grants listed in the full Funding Opportunity Announcement (FOA) that funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award, but were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for administrative supplements are considered prior approval requests (as described in Section 126.96.36.199 of the NIH Grants Policy Statement) and will be routed directly to the Grants Management Officer of the parent award. Although requests for administrative supplements may be submitted through this FOA, there is no guarantee that funds are available from the awarding IC or for any specific grant. All applicants are encouraged to discuss potential requests with the awarding IC. Additionally, prior to submission, applicants must review the awarding IC's web site to ensure they meet the IC's requirements.|
|Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)||National Institutes for Health/DHHS||None Posted||Not Available||The National Institutes of Health (NIH) hereby notify the applicant community that funds may be available for applications based on a presidentially declared disaster under the Stafford Act, a public health emergency declared by the Secretary, HHS, or other local, regional or national disaster. Applications in response to Emergency Notices of Special Interest (NOSIs) will be routed directly to the NIH awarding component signed on to the Emergency NOSI.|
|Covid-19 Scientific Research||European Synchrotron Radiation Facility||None Posted||Not Available||The ESRF is ready to provide access to its facilities for Covid-19 related research projects. This exceptional access will be granted with the aim to contribute to the international scientific effort to overcome the covid-19 pandemic.|
|Grants Program||COVID-19 Early Treatment Fund (CETF)||None Posted||Not Available||CETF will be funding initiatives that focus on treating outpatients with COVID-19 to prevent hospitalization. Grant recipients are required to share what they learn with others.|
|Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)||National Institutes of Health/DHSS||None Posted||Not Available||The National Institutes of Health (NIH) hereby notify Principal Investigators holding specific types of NIH research grants, listed in the full Funding Opportunity Announcement (FOA) that funds may be available for competitive revisions to meet immediate needs to help address a specific public health crisis in a timely manner, but that were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for Urgent Competitive Revisions will be routed directly to the NIH awarding component listed on the NoA of the most recent parent award. Only applications submitted in response to an Urgent Guide Notice published by an IC will be allowed to apply to this FOA.|
|2020 COVID-19 FlexGrants||West Coast Consortium for Technology & Innovation in Pediatrics||None Posted||$15,000||The West Coast Consortium for Technology & Innovation in Pediatrics (CTIP) is announcing a limited grant opportunity to support pediatric medical device innovators who are able to use their technology to aid in the current COVID-19 pandemic. Companies will be awarded grants up to $15,000 to support activities that apply or adapt their existing medical device to help manage the health impacts of the crisis on children. Medical devices with adult indications that are expanding or wish to expand their clinical indication to pediatrics are welcome to apply.|
|ICESCO Prize for Fighting Against Coronavirus||Islamic World Education, Scientific, and Cultural Organization||None Posted||$200,000||In response to the World Health Organization's appeal to the international community to "seize every opportunity to curb, contain, combat, and delay the spread of the virus, and mitigate its impact", the Islamic World Education, Scientific, and Cultural Organization (ICESCO) announces its Prize for Fighting Novel Coronavirus (COVID-19). The amount of the prize is US$200,000, including an award medal.|
|COVID-19 Response: A Call for Ideas||COVID-19 Response: A Call for Ideas||None Posted||Not Available||The Mercatus Center, building on its COVID-19 policy brief series, welcomes proposals for policy briefs, working papers, and articles that address the next round of challenges facing the United States and other countries in the response to the pandemic.|
|Access to Platform for Partner COVID-19 Projects||Ginkgo Bioworks||None Posted||Not Available||Ginkgo Bioworks has committed its platform to supporting research and development efforts for COVID-19, including $25M of free access to its infrastructure.|
|Expedited, Rapid Access Call for COVID-19 Research||Argonne National Laboratory||None Posted||Not Available||Argonne National Laboratory|
|COVID-19 Research Support||Brookhaven National Laboratory||None Posted||Not Available||The Center for Biomolecular Structure team is supporting remote macromolecular crystallography experiments at Beamlines 17-ID-1 (AMX) and 17-ID-2 (FMX) for research projects related to COVID-19.|
|COVID-19 Vaccine Development Award||MMS Holdings Inc.||None Posted||$1,000,000||The sponsor is offering a USD1M award toward the development of a vaccine for COVID-19, also known as the coronavirus. The award is being offered in the form of data and related services to qualified pharmaceutical and clinical research companies supporting the commercial development of a vaccine for approval in the United States and/or other global health authorities.|
|Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21 Clinical Trial Not Allowed)||Department of Health & Human Services||Rolling Submission||$275,000||The purpose of this Funding Opportunity Announcement (FOA) is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19).|
|Notice of Information: Contributing to the Global COVD-19 Crisis response by Allowing Some NCI-supported Projects to be Redirected to COVID-19-related Research During the Crisis||National Institutes of Health/DHSS||None Posted||Not Available||The COVID-19 pandemic is a global health crisis that has engaged the attention of researchers who want to be able to contribute their expertise and resources toward a better understanding of the impacts of SARS-CoV-2 infection and COVID-19 disease on cancer patients’ disease progression, response to therapy, care delivery, or survivorship. NCI anticipates that in infrequent cases, NCI-funded investigators will have novel insights and research proposals of immediate relevance to SARS-CoV-2 and COVID-19. In those cases, but only for the duration of the present crisis, NCI would consider requests from its funded grantees and cooperative agreement awardees to engage in limited COVID-19 related research using part of their existing NCI-funded resources.|
|Rapid Access for COVID-19 Research||Rapid Access for COVID-19 Research||None Posted||Not Available||With the continuing spread of the COVID-19 pandemic, the Department of Energy Basic Energy Sciences advanced neutron sources will provide remote rapid access to advanced user facilities to support research into the COVID-19 virus and the search for effective diagnostics and therapies.|
|COVID-19 Response Fund||International Associate for Volunteer Effort||None Posted||$500||The IAVE COVID-19 Response Fund will focus on supporting global volunteer leadership organizations working directly to respond to the pandemic among the most vulnerable populations in order to help build their capacity for response.|
|COVID-19 Rapid Response Fund||Southern Black Girls and Women's Consortium||None Posted||$10,000||The Southern Black Girls and Women's Consortium (SBGWC), a collective of funders, activists and community leaders working to advance the movements for black girls and women in the Deep South, is offering an immediate funding opportunity to support black girls and women and the people who rely on them due to the COVID-19 outbreak.|
|Deuteration & Macromolecular Crystallisation (DEMAX) COVID-19 related Research Projects||European Spallation Source||None Posted||Not Available||The Deuteration & Macromolecular Crystallisation (DEMAX) platform at ESS is offering prioritised access to laboratory services for scientists and researchers working on COVID-19-related research projects.|
|Ferring COVID-19 Investigational Grants||Ferring Pharmaceuticals||None Posted||EUR 25,000||Ferring is interested in funding exploratory, basic, and clinical research grants to collect data and expand knowledge about the effects on SARS-CoV-2 on reproduction, pregnancy, and foetal/neonatal health. The programme will provide a limited number of research grants up to €25,000 for each application.|
|COVID-19 Telehealth Program||Federal Communications Commission||None Posted||$1,000,000||The COVID-19 Telehealth Program will provide $200 million in funding, appropriated by Congress as part of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, to help health care providers provide connected care services to patients at their homes or mobile locations in response to the novel Coronavirus 2019 disease (COVID-19) pandemic.|
|PCORI Funding Opportunity for COVID-19-Related Enhancements to Existing PCORI-Funded Dissemination and Implementation Awards||Patient-Centered Outcomes Research Institute (PCORI)||None Posted||$500,000||PCORI seeks investigator-initiated proposals to address the COVID-19 public health crisis with enhancements to currently funded PCORI Dissemination and Implementation awards. Only PCORI-funded investigators or project leads with active Dissemination and Implementation Award contracts are eligible to submit a proposal in response to this announcement.|
|PCORI Funding Opportunity for COVID-19-Related Enhancements to Existing PCORI-Funded Research Projects||Patient-Centered Outcomes Research Institute (PCORI)||None Posted||$500,000||PCORI is currently seeking Project Lead-initiated proposals to address the COVID-19 public health crisis through enhancements to currently funded PCORI Engagement Awards. Only PCORI-funded project leads with active Engagement Award contracts are eligible to submit a proposal in response to this funding announcement.|
|PCORI Funding Opportunity for COVID-19-Related Enhancements to Existing PCORI-Funded Engagement Awards||Patient-Centered Outcomes Research Institute (PCORI)||None Posted||$150,000||PCORI is currently seeking Project Lead-initiated proposals to address the COVID-19 public health crisis through enhancements to currently funded PCORI Engagement Awards. Only PCORI-funded project leads with active Engagement Award contracts are eligible to submit a proposal in response to this funding announcement.|
|Artist Relief||Americans for the Arts||Not Available||$5,000||Artist Relief will distribute $5,000 grants to artists facing dire financial emergencies due to COVID-19; serve as an ongoing informational resource; and co-launch the COVID-19 Impact Survey for Artists and Creative Workers, designed by Americans for the Arts, to better identify and address the needs of artists.|
|SARS-COV-2 Diagnostics: Performance Data||Foundation for Innovative New Diagnostics (FIND)||Rolling Basis||Not Available||FIND is conducting independent evaluations of SARS-CoV-2 molecular tests and immunoassays. To complement these evaluations, and in partnership with WHO in line with the sponsor's official Collaborating Centre remit, the sponsor is endeavouring to centralize the collection of SARS-CoV-2 diagnostic performance data as a global public good. FIND is working closely with partners including the World Health Organization (WHO) in support of the global effort to combat the COVID-19 pandemic. In this respect, FIND is curating the overall diagnostic pipeline and tracking reported global diagnostic use, as well as conducting independent evaluations of SARS-CoV-2 molecular tests and immunoassays.|
|Prototype Development to Combat COVID-19||DOD - Department of the Army||Projected mid-2020||TBD||The Medical Technology Enterprise Consortium (MTEC) is excited to post this pre-announcement for a potential Request for Project Proposals (RPP) focused on the development of prototypes aimed to combat the coronavirus (COVID-19). In light of the magnitude and potential threat that the coronavirus (COVID-19) poses to our military’s health and readiness, the Government seeks to rapidly accelerate the inquiry, testing, and fielding of new 21st century capabilities, employing novel technologies and approaches to the detection of exposure, prevention, containment and treatment of COVID-19 and future emerging threats.|
|Priority Access Call for Work on Combating COVID-19||Scherre (Paul) Institute||None Posted||Not Available||The Paul Scherrer Institute (PSI) has opened a "PRIORITY COVID-19 Call” for short proposals and quick peer review to enable rapid access to beamtime. Research proposals shall have the potential to effectively contribute to the understanding of the COVID-19 virus and/or to improve the clinical or public health response and patient care.|
|NIH Small Research Grant Program (Parent R03 Clinical Trail NOT Allowed)||National Institutes of Health/DHSS||On-going (Currently 07-Sept-2020)||$100,000.00||The NIH Small Research Grant Program supports small research projects that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s).|
|RFP -- AMENDMENT --- BARDA's Division of Research, Innovation & Ventures (DRIVe) Easy Broad Agency Announcement||Department of Health & Human Services||Continuous||Not Specified||AMENDMENT: 3/9/2020 - Please see Special Instructions 003 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002. Under these Special Instructions, BARDA is adding several new topics under its temporary AOI #4: COVID-19 (renamed from 2019-nCoV) as part of its EZ-BAA (BAA-20-100-SOL-0002). AMENDMENT: 3/18/2020 - Please see Special Instructions 004 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.|
|Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)||National Institutes of Health (multiple ICs)||Varies by IC||Application budgets are not limited but need to reflect the actual needs of the proposed project.||The National Institutes of Health (NIH) hereby notify the applicant community that funds may be available for applications based on a presidentially declared disaster under the Stafford Act, a public health emergency declared by the Secretary, HHS, or other local, regional or national disaster. Applications in response to Emergency Notices of Special Interest (NOSIs) will be routed directly to the NIH awarding component signed on to the Emergency NOSI.
Only applications submitted in response to an Emergency NOSI published by an IC will be allowed to apply to this FOA.
|Dear Colleague Letter: Request for SBIR/STTR Phase I Proposals Addressing COVID-19 (NSF 20-065)||National Science Foundation||Four Submission Windows:|
3/6/ 2020 6/4/ 2020
6/5/2020 9/3/ 2020
|See SBIR/STTR Guidelines||The Division of Innovation and Industrial Partnerships (IIP) of the Engineering Directorate invites US-based small businesses to submit Phase I proposals focused on the development and deployment of new technologies, products, processes, and services with the potential to positively impact the nations and worlds ability to respond to the COVID-19 crisis. Areas of research that might be considered include, but are not limited to: artificial intelligence, digital health, diagnostics, distributed ledger, environmental technologies, medical devices, pharmaceutical technologies, disinfection and sterilization, and filtration and separations. Interested proposers are invited to submit to the NSF Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Phase I Program. All active NSF SBIR/STTR awardees, and other interested US-based small businesses are eligible to submit a Phase I proposal. Please reference the NSF SBIR and STTR Phase I solicitations for more details regarding eligibility.|
|Coronavirus Local Response Initiative||Bloomberg Philanthropies||Continuous Submission||Not Specified||Bloomberg Philanthropies will work with partners to identify the needs and lessons learned from cities experiencing the outbreak in real time that can be shared with additional cities eager to get ahead of the virus spread. Relying on public health expertise from the Johns Hopkins Bloomberg School of Public Health, the network will provide mayors with the most up-to-date information on the virus from the Centers for Disease Control and help them understand and act on the most relevant and accurate information available.
The program is open to all cities in the United States and will accommodate as many participants as possible. (tld)
|Dear Colleague Letter--Coronavirus Disease 2019 (COVID-19)||Department of Energy||Continuous Submission||Not Specified||Through its user facilities, computational power, and enabling infrastructure, DOE has unique capabilities that the scientific community may leverage for the COVID-19 response and recovery. DOE does not provide medical and clinical work; instead, the Department's mission complements the efforts of the National Institutes of Health, the Department of Defense, and other Federal partners by helping to understand the scientific phenomena contributing to COVID-19, from the structure of the SARS-CoV-2 virus, which causes the disease, to models that can mimic its spread. DOE supports significant biologically focused facilities and resources, including the Joint Genome Institute (JGI), National Microbiome Data Collaborative (NMDC), Environmental Molecular Science Laboratory (EMSL), and DOE Systems Biology Knowledgebase (KBase). These and other DOE resources may be used for many studies. The Department encourages submission of scientific questions that underpin COVID-19 response and that the research community may answer using DOE user facilities, computational resources, and enabling infrastructure. The Department is acting rapidly to leverage, and when appropriate provide prioritized access to, the full range of DOE user facilities and other facilities available at national laboratories to support the national and international effort to address COVID-19.|
|Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)||National Institutes of Health/DHHS||Varies by IC||Application budgets are not limited but need to reflect the actual needs of the proposed project.||The National Institutes of Health (NIH) hereby notify Principal Investigators holding specific types of NIH research grants, listed in the full Funding Opportunity Announcement (FOA) that funds may be available for competitive revisions to meet immediate needs to help address a specific public health crisis in a timely manner, but that were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for Urgent Competitive Revisions will be routed directly to the NIH awarding component listed on the NoA of the most recent parent award.
Only applications submitted in response to an Urgent Guide Notice published by an IC will be allowed to apply to this FOA. Individual(s) must hold an active grant or cooperative agreement, and the research proposed in the supplement must be accomplished within the competitive segment of the active award. Individuals are encouraged to work with their organizations to develop applications for support
|Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)||National Institutes of Health/DHHS||Varies by IC||Application budgets are limited to no more than the amount of the current parent award, and must reflect the actual needs of the proposed project.|| The National Institutes of Health (NIH) hereby notify Program Directors/Principal Investigators (PD(s)/PI(s)) holding specific types of NIH research grants listed in the full Funding Opportunity Announcement (FOA) that funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award, but were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for administrative supplements are considered prior approval requests (as described in Section 188.8.131.52 of the NIH Grants Policy Statement; https://grants.nih.gov/grants/policy/nihgps/HTML5/section_8/8.1_changes_in_project_and_budget.htm#Need) and will be routed directly to the Grants Management Officer of the parent award.
Although requests for administrative supplements may be submitted through this FOA, there is no guarantee that funds are available from the awarding IC or for any specific grant. All applicants are encouraged to discuss potential requests with the awarding IC. Additionally, prior to submission, applicants must review the awarding IC's web site to ensure they meet the IC's requirements. A list of those web sites is available at https://grants.nih.gov/grants/guide/admin_supp/index.htm.
|Dear Colleague Letter on the Coronavirus Disease 2019(COVID-19); NSF 20-052||National Science Foundation||Varies||Varies||In light of the emergence and spread of the coronavirus disease 2019 (COVID-19) in the United States and abroad, the National Science Foundation (NSF) is accepting proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge.
NSF encourages the research community to respond to this challenge through existing funding opportunities. In addition, we invite researchers to use the Rapid Response Research (RAPID) funding mechanism, which allows NSF to receive and review proposals having a severe urgency with regard to availability of or access to data, facilities or specialized equipment as well as quick-response research on natural or anthropogenic disasters and similar unanticipated events. Requests for RAPID proposals may be for up to $200K and up to one year in duration. Well-justified proposals that exceed these limits may be entertained. All questions should be directed either to a program officer managing an NSF program with which the research would be aligned or to email@example.com.
|Dear Colleague Letter: Provisioning Advanced Cyberinfrastructure to Further Research on the Coronavirus Disease 2019 (COVID-19); NSF 20-055||National Science Foundation||Varies||Varies||This Dear Colleague Letter (DCL) complements a separate National Science Foundation (NSF) DCL (NSF 20-052) that referred to the emergence of the coronavirus disease 2019 (COVID-19) and expressed NSF's interest in accepting proposals to conduct non-medical, non-clinical-care research that can be used immediately to better understand how to model and understand the spread of COVID-19; to inform and educate about the science of virus transmission and prevention; and to encourage the development of processes and actions to address this global challenge. Through this DCL, the Office of Advanced Cyberinfrastructure (OAC) within the Directorate for Computer and Information Science and Engineering is inviting RAPID proposals and supplemental funding requests to existing awards that address COVID-19 challenges through data and/or software infrastructure development activities. Such activities would be funded by the Computational and Data-Enabled Science and Engineering (CDS&E) program or the Cyberinfrastructure for Sustained Scientific Innovation (CSSI) program. Proposals in response to this DCL and the NSF DCL on COVID-19 (NSF 20-052) may also request the use of NSF-funded advanced computing resources such as Frontera, Stampede2, Bridges, Comet, and JetStream. To ensure availability of these computing resources, investigators must contact OAC prior to submission of the proposal.|
|Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)||National Heart, Lung and Blood Institute/National Institutes of Health/DHHS||Varies (NOSI Expires 10/06/2020)||Varies||NHLBI is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and on biological effects of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Topics of specific interest to NHLBI include host response, associations with heart, lung, and blood (HLB) diseases, potential impacts on transfusion safety, and clinical outcomes of infected individuals. To better understand the host response, associated HLB disease, impact on transfusion safety, and short- and long-term clinical outcomes of individuals infected with SARS-CoV-2, the NHLBI encourages the submission of applications for Administrative Supplements and Competitive Revisions to active NHLBI grants to support research on SARS-CoV-2 and HLB COVID-19 disease. Of particular interest are studies that take advantage of human research or unique model systems to study the consequences of SARS-CoV-2 infection. Supported research is expected to inform future efforts to diagnose, prevent, mitigate, or treat this viral infection and associated HLB manifestations. Applicants should be submitted using one of the two Supplement PAs (PA-18-591 and PA-18-935)|
|Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus||National Institute on Drug Abuse/NIH/DHHS||Varies (NOSI Expires 3/31/2021)||Varies||NIDA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19). NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders. As people across the U.S. and the rest of the world prepare for what could be a pandemic of the 2019 novel coronavirus, or COVID-19, the research community should be alert to the possibility that it could affect some populations with substance use disorders or HIV particularly hard. Because it attacks the lungs, COVID-19 could be an especially serious threat to those with histories of smoking tobacco or marijuana or of vaping. People who use opioids or methamphetamine may also be vulnerable due to those drugs effects on respiratory and pulmonary health and potential effects on immune mechanisms. Likewise, those with HIV may be affected if their immune function is compromised. Additional social and environmental factors associated with drug use may worsen the transmission and treatment of COVID-19, especially among individuals who experience homelessness or incarceration, which is more common among those with a substance use disorder. Applicants should be submitted using one of the two Supplement PAs (PA-18-591, where the work proposed in the supplement is fully within the scope of the ongoing grant; and PA-18-935, for grantees wishing to expand the scope of their active grant)|
|Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV)||National Institute of Allergy and Infectious Diseases (NIAID) and|
National Institute of General Medical Sciences (NIGMS)/NIH/DHHS
|Expiration Date of NOSI, 4/8/2020||Varies||NIAID and NIGMS are issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel Coronavirus (2019-nCoV). NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against 2019-nCoV. NIGMS is specifically interested in incorporation of data from the 2019-nCoV into ongoing research efforts to develop predictive models for the spread of Coronaviruses and related pathogens.
NIAID and NIGMS are therefore offering Competitive Revisions to active grants addressing research objectives described in the NOSI. Applications in response to this NOSI must be submitted using the following targeted funding opportunity: PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional), which is intended to provide funds for NIH grantees applying to expand the scope of their active grant. Further details can be found here: https://www.niaid.nih.gov/grants-contracts/urgent-award-mechanism. The funding instrument, or activity code, will be the same as the parent award.
Please note: NOT-AI-20-030 is specific for PA-18-935. NIH grantees seeking additional funds for research responsive to the 2019-nCoV outbreak that falls within the scope of an ongoing grant should instead apply for an administrative supplement under NIH PA-18-591, Administrative Supplements to Existing NIH Grants and Cooperative Agreements FOA (https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html).
|Competitive Fund for Peace and Recovery||Innovations for Poverty Action (IPA)||See website for deadlines and how to apply||$50,000||As COVID-19 spreads around the world, IPA's Peace & Recovery Program is accepting off-cycle proposals, capped at $50,000, for time-sensitive additions to research projects that study or support the COVID-19 response. Due to the limited funding available, this funding will likely not fund entire randomized evaluations, but is meant to support research projects with additions such as:
Adding a module to an existing survey in order to track COVID-19 exposure or response,
Adding a treatment arm that may support communities' resiliency in response to COVID-19,
Anonymizing, curating, and sharing already-collected data quickly so that it can be used for decision-making by the humanitarian community, or
Downstream surveys" that follow up on a sample that participated in an already-completed randomized trial in order to identify whether the intervention studied has an impact on the communities' response to COVID-19. Interested applicants should first send an email to firstname.lastname@example.org asking for more information on how to submit an off-cycle proposal.